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Abstract 
The potential psychosocial sequelae of epilepsy are well-documented, but it cannot 
be assumed that trajectories for quality of life (QOL) of people with epilepsy will 
inevitably follow its clinical course. In this paper, we draw on available literature to 
suggest likely QOL trajectories associated with epilepsy and the broad range of 
disease-, patient- and other-focussed factors that appear important in determining 
them. We conclude that both the likely shape and timeframe for QOL trajectories 
associated with particular clinical scenarios can be delineated; but that their shape 
can be altered by a much wider range of factors than those represented as epilepsy 
disease progression.  We identify contributory factors currently relatively unexplored 
and highlight implications for treatment and areas for future research.   
 
Word Count: 120 
Background 
 
Epilepsy is a generally benign clinical condition with a high likelihood of remission 
[1,2]. Around six percent of the general population will experience at least one 
seizure during the course of their lifetime [3], but many of them will never have a 
second [4], the risk of doing so decreasing with increasing time from the initial event 
[5]. Evidence from the small number of studies that have examined it suggest that 
antiepileptic drug (AED) treatment has little impact on the short or longer term 
likelihood of recurrence following a single seizure [6,7]. However, once an individual 
experiences a second seizure, treatment with AEDs becomes the norm as they then 
fulfil the commonly accepted (if arbitrary [8]) criterion for a diagnosis of epilepsy. In 
treated patients the likelihood of a remission of seizures is high, estimated at 
between 65% and 80%, though better for generalised than for partial epilepsies [4].  
In those patients in whom remission is prolonged, withdrawal of AEDs is generally 
considered, though the largest study to consider the outcomes of AED withdrawal put 
the risk of relapse in those doing so as twice that of those remaining on treatment [9].  
Around 20-30% of patients treated for epilepsy will fail to respond to treatment and 
will continue to have seizures: and only around 20% of these patients will have even 
short-lived seizure-free periods [4]. Many such patients will then wish to consider 
surgery for their condition, in the hope that removal of affected brain tissue will render 
them seizure free: and a review of the outcomes of surgical treatment worldwide 
shows that success rates are, indeed, high for most surgical procedures [10]. The 
various clinical trajectories described here are illustrated in Figure 1.           
 
Life expectancy is known to be reduced in people who develop seizures [11,12,13], 
with reductions being highest at the time of diagnosis.  Sander and Sillanpaa [4] note 
that mortality rates are highest among people under 40 years, a group that has the 
lowest mortality risk in the general population.  Rates are highest among those with 
generalised seizures and symptomatic epilepsy [14]. Epilepsy has a known 
association with increased risk of suicide, particularly shortly after diagnosis [15]. 
Deaths from accident and trauma are also more common than in the general 
population. Accident rates are increased in people with epilepsy (PWE) compared to 
the general population, though the increase is a modest one [16]. PWE are also at 
increased risk of suffering from other chronic conditions of ill-health [17,18]. In 
addition to these increased mortality and physical morbidity risks, epilepsy has well-
documented psychosocial sequelae – and it is these and their implications for overall 
quality of life (QOL) that are the focus of this paper.  
 One thing that is clear from available research evidence is that PWE as a group have 
poorer QOL than people without epilepsy [17,19,20,21]. For example, Strine et al [17] 
compared health-related QOL in a very large community sample of adults with and 
without seizures identified via the US National Health Interview Survey; and reported 
that, after adjustment for socio-demographic characteristics, those with seizures were 
more likely to experience psychological distress, sleep impairment, and pain; were 
more likely to be suffering serious mental illness; and were also more likely to be 
physically inactive and to have co-morbidities. They were also less likely to be 
married and in employment currently. A similar, earlier study in Canada drew on the 
1990 Ontario Health Survey and involved a large representative sample of the 
population of Ontario Province [19]. QOL was significantly poorer for those identifying 
themselves as having epilepsy than for either those with a chronic illness other than 
epilepsy or those who described themselves as healthy. Social participation indices 
were also significantly lower for PWE, as was participation in regular physical activity. 
Finally, PWE had lower annual income than their comparator groups and reported 
more disability days annually.  
 
Useful though such studies are, by treating all those reporting seizures as a single 
group, they tend to paint a grimmer picture than is necessarily suggested by research 
in which different groups of PWE are differentiated. Yet, as is pointed out by Wilson 
et al [22], for an individual patient developing seizures such differentiation is 
important and may help alert them and involved health professionals as to likely 
responses and requirements for intervention. Responses and interventions in this 
context will not only be clinical but also psychosocial, aimed not only at managing 
seizures but also at maximising QOL. It cannot be assumed that the trajectories for 
quality of life of PWE will de facto reflect its clinical trajectories; and elucidation of 
likely QOL trajectories and the wide range of factors contributing to them is therefore 
important.    
 
Within sociological studies of health and illness, the term ‘trajectory’ has been used 
to describe the course and timescale of events associated with phenomena such as 
dying, or the onset of a chronic illness [23]. In its original application, it was used to 
describe the efforts made by patients, their families and their professional carers to 
control the clinical course of chronic illness, prevent or manage its symptoms, live 
with any associated disabilities, and hence maintain good quality of life [24]. The 
trajectory framework has been applied to consideration of a range of chronic 
conditions, including cancer [25], diabetes [26], heart disease [27], multiple sclerosis 
[28,29] and stroke [30,31], though not, to our knowledge, epilepsy. In this paper, we 
utilise the term ‘trajectory’ not strictly as proposed by Corbin and Strauss, but for 
elucidation of the QOL course and timescale of QOL events resulting from 
developing seizures and epilepsy. We draw both on our own research into QOL in 
epilepsy and other available literature to suggest likely QOL trajectories associated 
with epilepsy and the broad range of disease-, patient- and other-focussed factors 
that appear important in determining them. We also attempt to identify possible 
factors currently relatively unexplored and to highlight areas for future research.   
 
Within the trajectory framework proposed by Corbin and Strauss, they delineate eight 
distinct phases typically seen in chronic illnesses (Box 1) the first six of which, we 
suggest, are applicable to the clinical course of epilepsy. Since Corbin and Strauss 
developed the framework in the context of the care of dying patients, the final two 
phases, ‘downward’ and ‘dying’ are less relevant; and it has been argued that the 
framework should also include a ‘recovery’ phase [32], since many chronic illnesses 
do not end in death and may even involve stabilisation at original levels of functioning 
and quality of life. In this paper, we will provide evidence of just such a likely 
trajectory for epilepsy and of the likely timescales involved. Acknowledging the 
limitations of their framework in this respect [33], its authors recognise that new 
health technologies can alter illness trajectories significantly. In the context of 
epilepsy, surgery represents an increasingly important technology and we will 
highlight the significant contribution it can have in altering QOL trajectories of those 
undergoing it.           
 
As highlighted in Box 1, the concept of an illness trajectory involves evolution over 
time; and tracking it therefore requires data that are longitudinal and preferably long-
term. For obvious reasons of complexity and costs, relatively few longitudinal QOL 
studies have been conducted in epilepsy and many of those that have follow their 
protagonists for relatively short periods of time only. As a result, much of the data 
drawn upon here derives from cross-sectional descriptive studies, involving specific 
epilepsy sub-populations (e.g. those with ‘active’ epilepsy, or those undergoing 
surgery) which, taken together, suggest certain likely trajectories for patients falling 
within a particular subgroup. However, there are also some longitudinal studies which 
have followed cohorts of PWE from the time of onset of their seizures over more 
extensive periods of time to explore subsequent QOL outcomes. Some of these 
studies involve adults with epilepsy whose seizures commenced in adulthood, others 
adults with epilepsy that commenced in childhood. Some studies have involved PWE 
only, while others have compared QOL in PWE with QOL in non-epileptic controls – 
either persons with other chronic conditions of ill-health, or healthy individuals, or 
both.  
 
Whether the source is cross-sectional or longitudinal, there are some significant 
limitations with the data available and with their interpretation. First, the numbers of 
patients involved in these studies are often quite small; and in the longitudinal 
studies, loss to follow-up means that the survivors may be those with either the most 
or least benign QOL trajectories - it may be the case that patients whose epilepsy 
impacts most on QOL feel least able to devote time to participation in research; 
conversely, those whose epilepsy has minimal QOL impacts may come to view such 
research as irrelevant to them, and so may abandon participation. Second, 
definitions of QOL are often unspecified and there may be questions about the 
ecological validity of both the definitions and the measures used to operationalize 
them, given potential variation in the importance of different QOL domains across 
different cultural groups. Third, even when comparing studies conducted in the same 
cultural setting, variation in the measures used to assess QOL makes comparison of 
findings sometimes less than satisfactory; likewise, in the published longitudinal 
studies, length of follow-up varies from as little as 12 months to as much as 30 years. 
Furthermore, many of the longitudinal studies involve only short-term follow-up, 
despite the fact that, as pointed out by Wilson et al [22,34] the processes involved 
are likely to be long-term. A further problem, specific to cross-sectional studies, is 
that they can demonstrate associations between hypothesised predictor variables 
and QOL outcomes, but cannot establish causal effects or the pin-pointing of key 
points in the QOL trajectory. Finally, virtually all studies exploring QOL outcomes in 
PWE are quantitative in nature, allowing definition of the size of the problem of poor 
outcomes, but with limited ability to shed light on the processes involved.  Despite 
these limitations, we can begin to piece together a picture of the different QOL 
trajectories associated with having epilepsy, and it is to this that we now turn. 
 
 
Search Strategy and Selection Criteria 
 
References for this review were identified by conducting electronic searches of the 
following databases: Allied and Complementary Medicine (1985 onwards), British 
Nursing Index (1994 onwards), CINAHL (1982 onwards), MEDLINE (1966 onwards), 
Science Direct (1995 onwards), and The Cochrane Library (2007). Subject search 
terms and combinations included: epilepsy, chronic illness or chronic disease and 
quality of life or health and quality of life, or trajectory or illness trajectory or quality of 
life trajectory, or outcomes and prognosis, or remission induction, or sickness impact 
profile.  The search was limited to adults (19 years and over) and only papers 
published in English were reviewed.  References were also identified from relevant 
articles and through searches of the authors’ own files.  The search is current up to 
October 2007.  
 
 
Findings 
 
Impact of a single or few seizures on QOL 
 
Given the threatened losses that the onset of seizures poses (including loss of 
employment, loss of the right to drive, loss of sense of control, loss of sense of self), 
it would be surprising if these were not reflected in some way in the QOL profiles of 
those individuals who experience them. Velissaris et al [35] conducted a 
phenomenological study using in-depth, semi-structured interviews to explore the 
psychological impact of a first seizure (in the Corbin & Strauss model, the trajectory 
onset) and noted that persons thus affected typically reported shock and fear at what 
had happened, anxieties about the possibility of seizures recurring, an increased 
sense of vulnerability and limitations on their social activities - reactions which 
collectively represented loss of control. In some patients this sense of lost control 
was pervasive, in others it was fairly limited; but by three months patients in both 
groups were reporting largely normal psychological functioning and those in the 
group experiencing pervasive loss of control were also reporting an improved sense 
of self.     
 
Dworetzky et al [36] compared quantitatively QOL of 30 adults experiencing a single 
seizure (PSS) with that of 29 adults with well-controlled epilepsy (PWC) and with 24 
adults recently diagnosed as having hypertension (PHT) – and likewise concluded 
that having a single seizure has only a modest impact on QOL.  All three groups of 
patients completed the SF-36 health status measure [37], as well as questions about 
the perceived impact of their condition, medication status and health care utilisation. 
At baseline interview, no significant differences were found between the three groups 
for any of the eight domains of the SF-36, for QOL overall, or for the perceived 
impact of their condition on QOL. However, PSS reported significantly higher use of 
healthcare services than did either of the two other groups; and this high usage 
continued through the year of follow-up perhaps, the authors suggest, because of the 
need to monitor responses to new medication taking.  When their scores on the SF-
36 were compared with age-adjusted population norms, PSS had significantly lower 
scores on the energy/vitality and physical role functioning domains, but their scores 
on the other six domains were comparable – despite the fact that over a third (38%) 
of PSS, when asked at follow-up, considered that their seizure had had a moderate 
to extreme impact on their QOL.  
 
Jacoby et al [38,39] reported 2-year QOL outcomes in patients with single or few 
seizures recruited to a randomised trial of opposing policies for management of 
single or few seizures. The policies in question were immediate treatment with AED 
medication or treatment deferred until such time as either the patient or the treating 
clinician deemed it necessary; and all patients were tracked for clinical outcomes for 
a minimum of one year. At the same time, they were asked to complete QOL 
questionnaires at the point of randomisation and two and four years subsequently. 
The results of the treatment comparison have been reported in detail [7] and are not 
the point of interest here – suffice it to say that in the long term pursuing a policy of 
immediate treatment offered no clinical advantage. Likewise, there were no QOL 
advantages of immediate treatment, with the single exception of driving status, where 
the advantage was for those treated immediately.  Of considerable relevance, 
however, was the finding that the QOL profile of patients reporting a single seizure 
only at randomisation was significantly better than that of patients reporting more 
than one seizure [38]. And though overall rates of employment at point of 
randomisation were lower than for the general UK population, those experiencing a 
single pre-randomisation seizure were around twice as likely to be in employment at 
that time point as were individuals experiencing two or three, and three times as 
likely as those experiencing four or more [40]: by four year follow-up employment 
rates for those having had a single seizure only were approaching UK norms.  
Furthermore, disregarding the number of seizures pre-randomisation, patients who 
remained seizure-free following randomisation had much enhanced QOL profiles at 
2-year follow-up compared to their counterparts with continuing seizures [39]. Taken 
together then, these findings support the conclusion that patients having a single or 
few seizures only will experience relatively few and relatively short-lived decrements 
to QOL.   
 
Finally, Lindsten et al [41,42] examined 10-year QOL outcomes in a cohort of 
individuals 17 years and over experiencing newly diagnosed unprovoked seizures 
(27% of whom had experienced only a single seizure) and their sex- and age-
matched controls. They reported that across the 10-year period, most leisure-time 
activities, marital and driving status were unaffected by the onset of epilepsy; and the 
negative effects that were noted (for physical activity, travelling abroad and overall 
activity) occurred later rather than earlier in follow-up, suggesting that factors other 
than seizures were the cause. The authors suggest a possible link between reduced 
leisure activity and the finding that PWE also reported reduced income compared to 
controls, and higher morbidity. However, they also note that in their cohort, PWE had 
significantly lower income levels than controls before the index seizure. Employment 
rates were similar for PWE and controls across the 10-year period and did not evolve 
negatively among PWE after the onset of their seizures (though there were 
differences between those who became seizure-free compared to those with 
continuing seizures). Thus, these authors too present a generally optimistic picture of 
the likely QOL trajectory of patients experiencing a single or few seizures, concluding 
that important QOL effects will be present only for those whose seizures do not remit.   
 
In summary, then, for persons experiencing a single or few seizures only, the 
trajectory suggested by the available evidence is one of a sudden dip in QOL 
immediately following the seizure event, followed by a fairly quick return (generally 
suggested as somewhere between 1 and 2 years) to (almost) normal functioning 
(when compared to the general population) and a life quality comparable to that 
which preceded the event (Figure 2).   
 
 
QOL in patients with active epilepsy 
 
Patients with active epilepsy are represented in the model by Corbin and Strauss as 
being in the acute phase of the chronic illness trajectory. Definitions of ‘active’ 
epilepsy vary across reported studies from seizures in the last two years [43] to 
seizures in the last three months [20], hampering direct comparison of findings.  
Nonetheless, seizure frequency has been heavily implicated in QOL across all these 
studies [20,43,44,45,46,47] and there is evidence too of a role for seizure recency.  
Baker et al [44] reported findings from a European-wide study involving over 5,000 
PWE, in which active epilepsy was defined as seizures in the previous 12 months (it 
is worth noting that around 95% of these individuals were also taking AEDs). There 
was a clear linear trend for QOL, with informants reporting at least one seizure per 
month in the previous year also reporting greatest impact of their epilepsy on daily 
functioning and scoring lowest on all eight SF-36 domains, and those experiencing 
no seizures in the last year reporting the least impact and scoring highest.  Leidy et al 
[45] studied QOL in 139 adults with active epilepsy, defined as seizures and/or AEDs 
in the last year, recruited from three US epilepsy centres.  Though the authors did not 
comment on it, this appeared to be a fairly disabled group of PWE, with only 35% 
reporting being in full-time employment despite a mean age of 38.5 years. The 
comparison made was between patients who were seizure-free in the previous four 
weeks, those having had between 1-5 seizures in that time period and those having 
had six or more.  Patients experiencing six or more seizures had significantly poorer 
QOL, as measured by the SF-36 health status measure, than those experiencing 1-5, 
who in turn reported poorer QOL than the seizure-free patients. In a multivariate 
model, seizure frequency, though not seizure recency, was associated with 
significantly poorer QOL. Leidy et al comment that while the meaning of any 
reduction in the number of seizures to patients themselves has still to be defined, the 
QOL differences detected in their study between patients experiencing 1-5 or 6 or 
more recent seizures are substantial, such that reducing seizure frequency by only a 
few, ‘could have a dramatic impact’. In a large US survey, Kobau et al [20] defined 
active epilepsy as either taking AEDs or experiencing seizures in the last three 
months; and reported a role both for seizure frequency and seizure recency in this 
group. Thus, 56% of those with active epilepsy reported only fair or poor health 
status, but the percentage rose to 75% in those who had had at least one seizure in 
the preceding three months. Adults with recent seizures also reported more 
physically unhealthy days, compared to those with active epilepsy but no recent 
seizures.         
 
In summary, all the available evidence suggests that having active epilepsy 
negatively and sometimes profoundly depresses QOL profiles; the subsequent QOL 
trajectory will be then influenced by whether the epilepsy remains active, progresses 
or remits, as will be shown below.  As will also be shown below, factors other than 
the clinical will also bear upon these QOL trajectories (Figure 2). 
 
 
QOL in patients with intractable seizures 
 
Studies focussing on patients with intractable epilepsy (the unstable phase in the 
Corbin and Strauss model) emphasise that in this subgroup potential QOL impacts 
are substantial [48,49,50,51,52]. Baker et al [48] showed for example, that compared 
to patients whose seizures were in remission, patients with intractable seizures 
scored significantly worse across all domains of the Nottingham Health Profile [53], 
as well as in relation to sense of mastery and self-esteem. Likewise, in the study by 
Vickrey et al [49] of 340 adults with refractory partial seizures evaluated pre-
surgically, QOLIE-89 [54] domain scores were considerably lower than has been 
reported for patients with well-controlled seizures, ranging from 43.6 for the epilepsy-
related domain to 47.5 for the mental health domain.  Perhaps unsurprisingly, in both 
these studies, seizure frequency emerged as less important than patient perceived 
seizure severity in predicting QOL. In Vickrey’s study, for example, correlations of 
QOLIE scores with seizure frequency were all non-significant, whereas those with 
seizure severity were significant even though modest (ranging from -0.17 to -0.29).  
The seizure severity item most highly correlated with QOLIE scores was post-seizure 
recovery time, with worse QOL associated with longer recovery time. Greater seizure 
severity was also negatively correlated with better employment status. These findings 
have led the two sets of authors – and, most recently, Harden et al [52] - to argue 
that in this particular subgroup of PWE, QOL improvements may be attainable simply 
by reducing the severity of seizures [52,55] and that the role of recovery time for QOL 
in patients with refractory epilepsy requires further elucidation [49].  Further 
confirmation for the minor role played by seizure frequency in the face of intractable 
epilepsy comes from Szaflarski et al [51]. The primary focus of their investigation was 
the effects of age-related factors on QOL in patients with drug-resistant epilepsy, but 
they also explored the effects of other epilepsy-related factors and mood. These 
authors did not consider the role of seizure severity in their analysis, but as in the 
studies already discussed, seizure frequency was found not to correlate with QOL.  
 
One likely reason for the lack of importance of seizure frequency in all these studies 
is highlighted by the work of Birbeck et al [56], who showed that in this group of 
highly disabled patients, reduction in the number of seizures did not translate into 
meaningful QOL improvements except where complete seizure freedom was 
achieved.  
 
In summary, we would suggest that the QOL trajectory of patients with intractable 
seizures will likely be subject to a series of peaks and troughs, with a range of factors 
other than seizure frequency determining its precise shape (Figure 2). Certainly, 
current evidence supports that QOL is substantially compromised by having 
intractable epilepsy; and for the small number of individuals who experience brief 
periods of seizure freedom, the disappointment and demoralisation when seizures 
recur may cause a major dip in QOL. The most likely scenario being the absence of 
any significant reduction in the number of seizures, reducing the perceived severity of 
those seizures may lead to an upturn in the QOL trajectory.  
 
QOL in patients undergoing surgery  
 
Perhaps because of the very large potential costs and benefits, the QOL outcomes of 
surgery for epilepsy have been much examined [22,34,57-77]. Most authors report 
QOL improvements: for example, Markand et al [67] found significant QOL 
increments, at one- and two-year follow-up, for surgically compared to medically 
managed patients, on 10 of the 17 domains of the QOLIE-89. There is, however, 
ongoing debate as to the nature of relationship between clinical and QOL outcomes 
of surgery.  Several authors [65,66,73] conclude that there is a post-surgical QOL 
continuum, whereby QOL is highest for patients rendered seizure-free or 
experiencing auras only and lowest for patients whose seizures are reduced in 
frequency by less than 75%. Other authors characterise QOL improvements post-
surgically as having a clear ‘cut-off’ point, which differentiates between those patients 
who attain complete seizure freedom and the rest [67].  
 
Whichever of these definitions ultimately prevails, the available data suggest that 
‘successful’ surgery can profoundly effect for the better QOL of those undergoing it 
and that QOL improvements can be sustained long-term [57, 59,63,65,69,76]. 
Spenser et al [72] followed a large cohort of patients undergoing surgery in whom 
they assessed QOL, using the QOLIE-89 measure, at intervals up to five years. QOL 
improved substantially across all outcome groups in the immediate post-operative 
period, then declined in those patients whose seizures persisted till it reached pre-
surgical levels. In contrast, QOL continued to improve in those remaining seizure-
free, with improvements levelling off at around two years when a QOL ‘ceiling’ 
appeared to be reached. Furthermore, this study and the one reported by Mikati et al 
[68] suggest that QOL can improve to the point of normalisation within a relatively 
short timeframe. In the former, the QOL scores observed for PWE at two-year follow-
up were similar to those observed for the general population on seven of the eight 
SF-36 scales (the exception being for social functioning). In the latter, the authors 
demonstrated that by three-year follow-up, QOL of patients undergoing temporal 
lobectomy did not differ significantly from healthy controls – a finding they attribute 
not only to the high level of surgical success (85% of patients became seizure-free), 
but also to factors such as the high level of social and family support offered. While in 
broad agreement with these conclusions, Markand et al [67] note that QOL 
improvements may be delayed in some domains compared to others. 
 
The broad message, then, seems to be that where it results in good seizure control 
surgery promotes good QOL and shifts people into a ‘recovery’ phase in terms of 
chronic illness trajectories [32]. There are, however, some important caveats to this 
general rule. Langfitt et al [64] report that QOL may actually worsen after surgery 
among a group of patients they refer to as ‘double losers’ (ie. where persistent 
seizures were accompanied by post-operative decrements in memory function). Von 
Lehe et al [73] report that even patients achieving good seizure control experience 
only modest benefits when the outcomes addressed relate to objective socio-
economic status rather than subjective life quality.  Post-surgical QOL has been 
shown to be predicted by pre-surgical QOL independent of seizure status [77], a 
finding paralleled in studies of the outcome of drug therapy {39,78,79]. Furthermore, 
patients’ pre-surgical expectations for QOL post-surgically are important 
determinants of their perceptions of its success [74]; and Wilson et al [75] have 
reported what they refer to as a paradox of cure, namely that patients may report 
QOL decrements despite clinical improvements post-surgically because of the 
difficulties faced in reconceptualising their personal identity as one without epilepsy 
[34] and the resultant the ‘burden of normality’. Nonetheless, the message from their 
work is in agreement with the one proposed by others cited above, in that despite 
initial difficulties in adjusting to life without seizures, adjustment trajectories for the 
majority of operated patients culminated in ‘psychosocial success’ by the time of two 
year review [22].   
 
In summary, the QOL trajectory varies post-surgery largely in line with clinical 
outcome. Surgery is followed immediately by an upturn in the trajectory, which is 
gradually reversed if the clinical outcome is poor; the upturn continues for some time 
where the clinical outcome is good, though the ‘burden of normality’ may mean the 
shape of the curve is not necessarily a smooth one; the trajectory levels off at around 
two to three years after surgery (Figure 2).      
 
 
QOL in patients seizure-free and in remission 
 Epidemiological studies highlight that patients with epilepsy in remission (variously 
defined as seizure-free for one or two years) constitute the largest group of PWE, 
(between 60-70% of all patients); and the collective message from studies of QOL in 
adults is that remission of seizures following pharmacological treatment, like 
successful surgery, is associated with the recovery phase of the chronic illness 
trajectory and a return to near-normal functioning [80,81,82,83,84].  For example, in 
Jacoby’s study [80] of 607 persons living in the UK, three-quarters of whom were in a 
remission of at least two years, dysfunction as measured by the six domains of the 
Nottingham Health Profile (energy, pain, emotion, sleep, social isolation, physical 
mobility) was minimal; and only small percentages were concerned about their 
epilepsy, felt stigmatised by it, or felt socially restricted by it. Furthermore, there was 
little evidence of social activity being reduced and employment rates were near those 
of the normal UK population. In the Norwegian study reported by Stavem et al [81], 
70% of those taking part were seizure-free in the previous year; and their SF-36 
scores were close to the normal population. Raty et al [84] reported on young adults 
specifically (aged 18-27 years) with uncomplicated epilepsy (ie. without any 
associated neurological impairment) and concluded that their condition affected their 
QOL ‘to only a small degree’.  Finally, though in the study by Leidy et al [45] the 
focus was on seizure frequency in the last month, it is worth noting that for those 
classified as seizure-free the median time since their last seizure was 365 days 
(compared to 6.5 and 1.5 days in the other two groups): the finding that SF-36 
domain and summary scale (mental and physical health) scores for seizure-free 
patients were similar to those for the general US population is therefore unsurprising 
in light of findings from these other studies.  Hessen et al [83] suggest an important 
role for neuropsychological function in determination of the QOL trajectory for 
patients who attain seizure freedom: these authors found that in adults seizure-free 
for at least two years, neuropsychological function was in the normal range, and 
educational and employment status were also similar to the general population 
mean.     
 
One interesting finding from the UK community study reported by Jacoby et al [43] 
was that though there were marked differences in QOL between patients 
experiencing seizures and those seizure-free in the year prior to study, increasing 
length of seizure freedom beyond this was not associated with increasing QOL – the 
relationship appeared to be a dichotomous rather than a linear one. Thus there were 
no significant differences in the percentages reporting anxiety, depression or felt 
stigma, or currently in employment when those reporting periods of seizure freedom 
of 2-4 years, 5-9 years and 10 or more years were compared. One explanation for 
this finding suggested by the authors is that the sample studied included a large 
percentage of PWE who had opted to remain on AED therapy despite long periods of 
remission; and continuing AED treatment has been shown to have adverse effects on 
psychosocial outcomes [85,86]. In Jacoby’s study, these individuals may therefore 
have had a poorer QOL profile than would individuals with a remote history of 
seizures who had opted to withdraw from AEDs and so were not eligible for inclusion.   
 
A challenge to the broad conclusion from the above literature that seizure freedom 
equates to good QOL comes from the recently published study by Kobau et al [20], 
wherein individuals with a history of seizures, however distant, reported impaired life 
quality. For example, 47% of those with a history of epilepsy reported fair or poor 
health status compared to only 20% of those without such a history; they also 
reported around double the number of physically and mentally unhealthy days and 
activity limitation days.  This may however, simply reflect that the definition of ‘active’ 
in this study was a much narrower one (seizures and/or AEDs in the last three 
months) than that employed in other studies focussing on remission.  Though on a 
much smaller scale, the study by Argyriou et al [87] supports the findings of Kobau et 
al, with no reduction in psychological function as measured by presence of anxiety or 
depression, but clear reductions in physical and social function, when persons with 
uncomplicated, well-controlled epilepsy were compared to healthy controls. The 
authors of this latter study attribute the negative QOL outcomes they document to 
stigma, a point we return to below, as well as to lack of epilepsy services and the 
repercussions of such for assessment, management and awareness in the rural area 
in which their work was conducted.            
 
In summary, the evidence suggests an upward trajectory for remission - albeit 
following a more prolonged period of QOL disruption than for those experiencing only 
single or few seizures -  leading to near-normal functioning. Again, two years appears 
to be a critical cut point for QOL improvements (Figure 2). 
 
 
Role of other epilepsy variables 
 
Generally speaking, the observed associations between QOL and other epilepsy-
related variables are weaker than those between QOL and seizure activity [72]. 
Jacoby et al [43] examined the effects of current seizure activity, seizure type, 
aetiology, age at onset and duration of epilepsy in a multivariate analysis: current 
seizure activity explained most variation in QOL function and was the only clinical 
variable predicting perceived impact of epilepsy and personal fulfilment scores; age 
and onset and duration were important in explaining depression scores; age of onset 
was also important in relation to felt stigma scores. There was some evidence that 
seizure type was associated with employment status, a finding reported elsewhere in 
the literature [88,89,90]. Timing of seizures has been suggested as important for 
QOL [47], perhaps because of the threats daytime seizures pose to safety, but also 
to the concealability of epilepsy and avoidance of stigma – a point we return to 
below.     
 
In contrast to the relative unimportance of these epilepsy variables, the literature 
increasingly points to an important role for adverse effects of AED treatment 
[47,91,92,93] in depressing QOL of those taking them; and of the potential for QOL 
increments if AEDs can be withdrawn [94]. Boylan et al [92] express concern that an 
over-enthusiastic focus on treating seizures pharmacologically may actually reduce 
QOL by increasing the risk of AED-related depression (the role of which we return to 
below).  Reduction of AED adverse effects is likely therefore to lead to an upturn in 
the QOL trajectory, even where no other changes in clinical status occur. 
 
 
Role of non-epilepsy factors in determining QOL trajectories 
 
Non-epilepsy factors identified as contributing to QOL among PWE fall into two broad 
categories: those that further increase vulnerability to impaired QOL and a downward 
trajectory; and those appearing to promote resilience (ie. an individual’s capacity to 
overcome adversity) and enhanced QOL, even in the face of important clinical 
factors.  A substantially greater body of work to date has addressed the former than 
the latter; for which reason we consider them first. 
   
Psychiatric co-morbidity: A rapidly expanding literature addresses the major 
contribution psychiatric factors, particularly anxiety and depression, make to 
perceived QOL of PWE [47,92,95,96,97,98,99,100,101,102,103,104]. The 
prevalence of both disorders is high in PWE, estimated as between 10-25% for 
anxiety [105] and between 10-60% for depression [106]. In a large sample of adults 
completing the 2004 US Healthstyles Survey [101], those self-reporting epilepsy 
were twice as likely to self-report anxiety or depression in the previous year than 
those without epilepsy and those with active epilepsy (defined as seizures in the last 
three months or on AED medication) were three times more likely.  Reduced QOL 
among PWE with depression, compared to PWE who are depression-free, is 
commonly reported [98,100,104]. Zeber and colleagues found QOLIE-89 scores to 
be significantly reduced by comorbid depression for all types of seizures [104]. A 
number of authors [99,100,107] provide evidence to suggest that clinical and socio-
demographic factors play only modest roles in determining QOL of PWE, while 
depression primarily, but also anxiety and seizure concerns exert powerful 
independent effects, explaining most of the variance in QOL scores. In line with this 
finding, Attarian et al [108] found no relationship between seizure intractability and 
severity of depression, which was as prevalent in patients seizure-free for six months 
or longer as in patients who experiencing continuing seizures.  Boylan et al [92] note 
that in their study of patients with refractory epilepsy, depression was common, 
severe, under-diagnosed, largely untreated and a powerful determinant of QOL, 
whereas seizure-related factors were not. So strong was the association between 
depression and QOL in the study by Tracy et al [107] that its authors posit that, ‘any 
therapeutic intervention observed to improve ‘quality of life’ . . . must at least consider 
the possibility that the outcome is strongly related to alteration in mood, not 
betterment of the underlying neurological or medical condition.’   
 
Other co-morbidities: Related to psychiatric morbidity, links have been shown 
between QOL and neuropsychological function generically [109], memory function 
specifically [95], sleep disturbance [110,111] and fatigue [47]. Additionally, medical 
co-morbidities have been shown to be more common in PWE  [17,18] and also linked 
to impaired QOL [45,58,112]. Pulsipher et al [112] report that increased number of 
co-morbid conditions was associated with decreased QOL, and that co-morbid 
medical and psychiatric conditions together accounted for almost 14% of the 
variance in QOL scores.  The number of co-morbid psychiatric conditions better 
predicted scores for psychosocial satisfaction, epilepsy related effects and cognition; 
whereas the number of co-morbid medical conditions better predicted role limitations 
and physical performance.  
 
Stigma: Finally, there are almost certainly important social context effects [113] and a 
role for stigma in determining the shape of QOL trajectories in epilepsy 
[114,115,116]. For example, Jacoby [117] showed that people whose epilepsy was in 
remission rarely reported feeling stigmatised: but those who did were more likely to 
report anxiety about epilepsy, had reduced scores for mastery and self-esteem, 
poorer psychological function, and more future-oriented uncertainty. Likewise, Baker 
et al [118] in a European-wide study involving over 5000 patients with epilepsy 
reported that high scores on a stigma scale were correlated with worry, negative 
feelings about life, long-term health problems, injuries, and reported side effects of 
AEDs. Stigma perception also contributed significantly to QOL in the study by 
Suurmeijer et al [119], alongside psychological distress and loneliness. These non-
clinical factors appeared to act as mediators of the effects of clinical variables such 
as seizure frequency.  DiIorio et al [120] note that perceived stigma is associated with 
decreased self-efficacy among PWE, perhaps creating a vicious circle of negative 
effects wherein poor self-efficacy leads to poor self-management of epilepsy and so 
to increasing disease severity and increasing stigma.  
 
Cerebral reserve: With regard to QOL promoters, research has highlighted a role for 
what can broadly be referred to as aspects of ‘resilience’. For example, Oyegbile et al 
[121] highlight the role of ‘cerebral reserve’ (as indicated by higher educational level 
and/or occupational attainment and/or increased participation in mindful activities) in 
modifying cognitive morbidity in PWE. They showed that though degree of 
generalised cognitive impairment – a major contributor to disease burden - was 
associated with duration of epilepsy, the association was attenuated by having more 
years of formal education (and, indeed, ceased to be significant). The authors 
suggest that years of education may, in fact, be a marker ‘for those who, at the outset 
of the disorder, are on different trajectories’ with regard to educational attainment and 
lifespan cognition – and, by implication, QOL. Other studies reporting educational 
level as a predictor of QOL in adults include those by Loring et al [100] and Pulsipher 
et al [112].  Wakamoto et al [122] examined long-term outcomes in individuals with 
childhood-onset epilepsy now aged 20 years and older; and concluded that where 
patients were of normal intelligence the prognosis was favourable. 
 
Self-efficacy and social support: Self-efficacy and mastery have been suggested as 
important for good QOL [80, 120,123,124,125], as has having access to good social 
support [123,125]. In the study by Amir et al [123], the group of interest was patients 
with chronic, intractable epilepsy: and unsurprisingly the more severe their epilepsy, 
the more impaired their life quality. However, the negative effects of disease severity 
were mediated by having a high sense of control. There was also a strong 
association between disease severity and levels of social support and between levels 
of social support and QOL – the authors argue that social support can be seen as, ‘a 
mirror image of social stigma’ whereby, ‘the quality of the social network becomes 
the evidence of social rejection (or acceptance) for the individual.’ They conclude that 
PWE do not necessarily need to see an improvement in the clinical features of their 
condition to see an improvement in their QOL, since this is also attainable by 
focussing on improvements in these other non-epilepsy related aspects of their 
existence.    
 
Optimism: Other ‘resilience’ focussed factors examined in the literature on QOL in 
epilepsy are those of positive affect [124] and optimism [126]. In the study by Pais-
Ribeiro et al [126], seizure frequency and severity emerged as unimportant, whereas 
having an optimistic orientation to their condition and a perception of their cognitive 
function as good were strongly predictive of PWE’s physical and mental health and 
overall QOL. The authors suggest therefore that interventions ‘with an impact on 
perception of cognitive function and/or epilepsy-specific optimistic orientation can 
have a profound effect on the lives of individuals with epilepsy’; and that patient 
support groups should aim to foster positive expectations of life with epilepsy among 
their members.  Finally, though rarely referred to in the literature, the contribution of 
spirituality to QOL was explored by Giovagnoli et al [127], who documented 
significant correlations between aspects of spirituality and overall QOL (as measured 
by the WHO Spiritual, Religious and Personal Beliefs Scale [128] and WHOQOL 100 
[128] respectively).       
 
In summary, then, research across a wide range of variables potentially contributing 
to QOL trajectories for PWE suggest a minor role for most clinical ones other than 
seizure activity, the obvious exception being AED effects. There is increasing 
evidence that the QOL trajectory will be depressed for individuals who experience 
psychiatric morbidity and stigma. The role of resilience, in its broadest sense, for 
enhancing QOL trajectories in epilepsy has yet to be fully explored; however, 
previous research suggests it will be important to utilise the concept of resilience as 
referring not simply to individual traits such as self-efficacy and spirituality, but to a 
process also involving external factors such as the presence or absence of social 
capital and support.   
 
 
Role of age of onset of epilepsy 
 
A point that requires emphasis here is that the studies reported above relate to QOL 
trajectories as suggested by the literature on epilepsy developing predominantly in 
adulthood. Studies specifically tracking outcomes in adulthood of childhood-onset 
seizures present a rather different picture, with long-term and often substantial QOL 
deficits clearly apparent  [86, 122,129,130,130,131]. In the cohort of 100 patients 
followed by Sillanpaa and colleagues, adult QOL across a number of domains was 
impaired compared to that of healthy controls, despite that their epilepsy was 
uncomplicated by any neurological impairment or disability. Thus, as adults these 
patients reported poorer physical fitness, though not self-assessed health status 
[132]; higher levels of co-morbidity, particularly psychiatric co-morbidity [129]; were 
less likely to marry and had fewer children [130]; had poorer educational level and 
were less likely to be in employment [131]; had lower socioeconomic status [86] and 
were less likely to be satisfied with their present life [131]. The authors conclude that 
childhood-onset epilepsy has a ‘persistent long-term adverse impact’ on QOL even in 
patients in remission [86]. An important positive finding in this otherwise fairly gloomy 
trajectory – and one supportive of Jacoby’s findings [80] in relation to adults with 
epilepsy in remission - is that where patients had both entered remission and been 
able to withdraw successfully from medication, the QOL impacts were relatively 
modest, with no significant differences between them and their healthy controls for 
health, employment or socioeconomic status and low reported self-perceived impacts 
of their condition. The same conclusion was drawn by Shackleton et al [133], who 
retrospectively surveyed a cohort of patients newly diagnosed with epilepsy in 
childhood and adolescence, some 30 years after diagnosis. Significantly fewer of the 
group with epilepsy than in the general Dutch population were married and 
significantly more lived alone. Both educational achievement and employment status 
were impaired in PWE compared to the rest of the Dutch population. As in 
Sillanpaa’s study, patients who fared best for QOL were the group who were seizure-
free and no longer taking AEDs.  
 
   
What can be done to promote good QOL trajectories? 
 
Bury [134] notes that chronic illness is, ‘by definition, a long-term and perhaps 
permanent event in a person’s life’, for which reason the experiences of those with 
chronic illness need to be placed ‘within a temporal framework.’  In this review, we 
have tried to identify studies that allow the temporal framework of epilepsy to be 
explored, starting with the experience of a first seizure and the initial disruption to 
QOL it causes and working through the subsequent clinical scenarios and their 
commonly reported QOL concomitants.  Analysis of the available data allows some 
(albeit fairly tentative) conclusions to be drawn both about the likely shape of the 
QOL trajectory associated with a particular clinical course for the epilepsy and to 
suggest some broad time frames around its execution. However, as is now clear from 
the literature, QOL trajectories will not inevitably mirror the clinical course of epilepsy. 
Their shape can be altered in highly individualistic ways by a much wider range of 
factors than those represented as epilepsy disease progression.  Hence, they may 
take a downward slope, even where seizures are well-controlled, in the presence of 
factors such as other medical or psychiatric co-morbidity, continued treatment with 
AEDs, experienced stigma and discrimination or, as illustrated in relation to surgery 
[22] difficulties in adjusting to being well. Conversely, the slope may move upwards 
despite continued seizures in the presence of high levels of personal and social 
capital or social support; and they may, of course, reach a point of stability. As 
Robinson [135] notes in the context of another neurological condition, MS, ‘the 
trajectories of the medical course, the social career and the personal narrative may 
be substantially different – for the reference points of the personal, social and 
biomedical are at variance.’ If we can understand and take account of the reference 
points for the personal meanings PWE attach to their condition and the formal and 
informal social implications that accompany it in any particular social context, we can 
then begin to make sense of how these interact with its biomedical features to create 
a particular QOL trajectory – and, by extension, what the foci of interventions aimed 
at altering negative QOL trajectories should be. 
 
Social scientific studies of chronic illness offer a number of concepts useful for 
explaining the personal impacts of a diagnosis of epilepsy. First, chronic illness has 
been characterised as a situation of uncertainty about aetiology, progression and 
severity and unpredictability of symptom manifestations within which patients face a 
psychological juggling act, balancing the hope of remission against the dread of 
regression [136]. Second, chronic illness has been conceptualised as a particular 
kind of disruptive life experience [24,137]: with disruption of taken-for-granted 
assumptions and behaviours; of the normal rules of reciprocity with others and 
mutual support; and of a person’s life biography. Though the concept of ‘biographical 
disruption’ has been subject to criticism for its failure to address the issue of 
biography for illness developing in childhood and to take account of events seen as 
‘normal crises’ [138] we consider it still a useful concept for consideration of the 
potential QOL impacts for adults with epilepsy. Third, chronic illness has been 
highlighted as ‘a fundamental form of suffering’ characterised by loss, particularly the 
loss of a sense of self [24,139] but also of the body because of the associated 
functional limitations. The relevance of all these concepts to epilepsy is self-evident.  
Epilepsy is a condition of sudden onset, where the cause is often unknown, and its 
physical manifestation, seizures, are unpredictable.  PWE hope for remission and 
may be prepared to tolerate unpleasant treatment side effects in order to secure it, 
but even those who become seizure-free are counselled that epilepsy is controllable 
rather than curable, and there can be no guarantee that seizures will not recur. 
Epilepsy is a disruptive life experience, wherein those affected may suddenly find 
themselves forced to confront the negative stereotypes they and significant others 
hold about epilepsy [140], the restrictions epilepsy and its treatment can impose on 
their everyday activities [141], the changing nature of their interpersonal relationships 
and possible increased dependence on others [115,142], and the potentially negative 
implications for the future. Epilepsy is also a condition of loss, wherein seizures bring 
sudden and total loss of bodily function and psychological losses such as reduced 
self-esteem or sense of mastery are commonly reported. In Bury’s [137] study of 
people who developed rheumatoid arthritis, the main problem they identified in light 
of such losses was learning to live with their condition. People developing epilepsy 
likewise have to learn to live with it; and it is not surprising that in the initial stages of 
this learning process, many experience a downward QOL trajectory.   
 
In contrast to these somewhat negative reflections on the nature of the experience of 
chronic illness, the social science literature also offers a more positive take on 
chronic illness and its implications for QOL.  Williams [143] argues that human beings 
are constantly engaged in a process of interpretation of the incidents and events of 
their daily lives, so that they can be imbued with some sense of order. Though the 
sense of order is thrown into disarray by the onset of chronic illness, it can, he 
argues, be restored by a process of ‘narrative reconstruction’ which allows them to 
accommodate what has happened and to ‘reconstitute and repair ruptures between 
body, self and world.’ This is akin to the concept of the burden of normality [75], 
where the clinically successful epilepsy surgery patient has to repair ruptures 
between the self that was with seizures and the self that is now seizure-free.  
 
Ormel et al [144] also offer a useful framework for understanding likely QOL 
trajectories, grounded in Social Production Function Theory [145].  This theory 
assumes that people produce their own well-being by trying to optimise achievement 
of universal needs within the constraints they are facing. Applying it in the context of 
chronic illness, Ormel and colleagues propose that at the onset of such illness, 
symptoms (in the case of epilepsy, seizures) and functional limitations (which in the 
case of epilepsy might be emotional or cognitive impairments) impair activities and 
increase the costs associated with achievement of life goals, leading to an immediate 
downturn in QOL.  Substitution of alternative activities allows a subsequent upturn in 
the QOL trajectory, even in the face of seemingly major reductions in functional 
abilities.  Ormel notes that the more options for substitution that are available to 
them, the less vulnerable people will be to the impact of the original losses; and that 
the breadth of such options is likely built up over the life course.  This may help to 
explain the very different QOL trajectories seen for people whose epilepsy develops 
early in life compared to those where it develops later – since the former group have 
less time and opportunity to develop options and possibilities for substitution. The 
conclusion of Ormel’s analysis is that addressing factors that limit the process of 
substitution and providing resources or enhancing the ‘behavioural repertoire’ that 
encourage it will have a beneficial effect for QOL, shifting the trajectory upwards.              
 
As evidenced by the various studies included in this review, patients are likely to 
require a period of adjustment at both ends of the clinical course of epilepsy – either 
to starting having or to no longer having seizures.  They are therefore likely to require 
interventions in the form of psychosocial and vocational counselling at both time 
points, either to learn to live with the limitations epilepsy can impose or to becoming 
well. Even a single seizure threatens biographical disruption and hence creates the 
conditions for psychological distress and fear of stigma (as was seen in the studies 
by Jacoby [39] and Velissaris [35]); but such disruption may be containable if no 
further seizures occur – hence the findings that QOL impacts of persons 
experiencing single seizures are fairly modest and short-term.  For those less 
fortunate individuals whose seizures continue, the threats in terms of disruption and 
loss become much larger, and the implications for QOL more significant and longer-
term. Examining the impact of reducing seizure frequency in such individuals, 
Birbeck et al [56] conclude that QOL is only really substantially improved if they 
achieve complete seizure freedom. It has been shown that this happy state of affairs 
may be attainable through drug treatment changes even in patients with apparently 
drug-resistant chronic epilepsy, though the success rate is relatively small [146]. 
Nonetheless, this finding highlights the need for clinicians to take a proactive 
approach to management of such patients, for whom the QOL benefits are likely 
substantial.  Surgery also offers the possible of seizure freedom and recovery; and it 
has been argued that it should be undertaken earlier rather than later in the clinical 
course of epilepsy, in order to maximise QOL benefits [147].    
 
Assuming seizure freedom is not attainable by either means (and accepting the 
caveats around seizure freedom as necessarily equating to high QOL) we agree with 
Johnson et al [99] about the need for greater emphasis on the recognition and 
treatment of co-morbid psychopathology among PWE. We also support the 
suggestion by Amir et al [123], directed at resilience rather than vulnerability, of the 
provision of workshops to improve sense of mastery and self-efficacy. These authors 
comment that the secondary effect of such workshops would be to create a sense of 
heightened social support, another important contributor to resilience. Helde et al 
[148] report support and counselling, in the form of a structured nurse-led 
intervention, can improve QOL of patients with uncontrolled seizures, at least in the 
medium term.  Interestingly, the timeframe chosen for assessment of effectiveness 
was two years, at which point QOL improvements from baseline seen in the 
intervention arm were not significantly different from those seen in the control arm. 
Since the various studies cited in this review indicate that two years is a critical point 
in the adjustment process, Helde’s findings may simply be a reflection of an 
adjustment process that would have occurred even without any intervention.  
Nonetheless, the core elements of a brief (1-day) interactive education session, 
followed by ongoing telephone-based nurse contact and support, are fairly easily 
performed and given the QOL effects observed, it would be valuable to replicate the 
study to see both if and why the findings are sustainable.  
 
As Wilson et al [22] have pointed out, attempting to define QOL trajectories for 
people with epilepsy is a highly complex process and one which emphasises the 
highly individual nature of responses to its diagnosis, treatment, control and 
remission and the process of adjustment.  We readily acknowledge that the 
applicability of the trajectories we propose here is limited by resting on research 
relating to groups of patients rather than individuals.  Nonetheless, we would argue 
they represent a useful framework for broadly summarising the available evidence 
and extrapolating certain common patterns. Many people with epilepsy will, we think, 
find these patterns helpful and even reassuring, while being only too well aware of 
their own particular life circumstances and responses. Based on currently available 
evidence, we conclude that QOL trajectories in epilepsy follow fairly closely its clinical 
course, but that they do so is not inevitable, and a wide range of factors mediate the 
relationship. For this reason, management of clinical symptoms at every phase of the 
epilepsy process should be routinely backed by management of psychosocial 
difficulties. We now need further research to elicit the competing influences of the 
various groups of factors. In particular greater emphasis needs to be given to aspects 
of resilience and the ability of PWE to accept and overcome adversity and so 
maintain or restore a high QOL.  
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 Box 1: Phases in the Chronic Illness Trajectory 
 
Phase: Definition: 
  
Pre-trajectory Before illness course begins, no signs/symptoms present 
Trajectory onset Signs/symptoms present; diagnostic period 
Crisis Life-threatening situation requiring emergency/critical care 
Acute Active illness and/or complications 
Stable Illness course/symptoms controlled by treatment regimen 
Unstable Course/symptoms not controlled 
Downward Progressive deterioration; increasing disability/symptoms 
Dying Time immediately preceding death 
(Adapted from Corbin & Strauss [33]) 
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